Beatrice L. Brown joins Ethics Talk to discuss her article, coauthored with Dr Aaron S Kesselheim: "How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?"
Divya Yerramilli, MD, MBE, Alexandra Charrow, MD, MBE, and Arthur Caplan, PhD
Physicians should be aware of the powerful impact celebrities’ cancer narratives can have on patients’ experiences of their illnesses and treatment decisions. Partnering with celebrities is one strategy for delivering evidence-based health information and messaging to the public.
AMA J Ethics. 2018;20(11):E1075-1081. doi:
10.1001/amajethics.2018.1075.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?
Patrick S. Phelan, Mary C. Politi, PhD, and Christopher J. Dy, MD, MPH
During immediate and long-term recovery periods, decisions must account for patients’ personal goals and possible clinical outcomes and should clarify what recovery means.
AMA J Ethics. 2020;22(5):E380-387. doi:
10.1001/amajethics.2020.380.